Our finding is in line with a report where a marked increase in CD59 levels was observed in both MM cells localized in the bone marrow, as well as in circulating MM cells during daratumumab treatment.25,37 Importantly, pretreatment with Ad35K++ during the second cycle of mAb/NHS treatment resulted in significant CDC, indicating that Ad35K++ can partially overcome resistance to mAb treatment. Here, CD59 is linked to Miyoshi myopathy.